Washington, D.C. — Congressman Michael C. Burgess, M.D. (R-TX), Chairman of the Energy and Commerce Subcommittee on Health, today released the following statement after President Trump signed the FDA Reauthorization Act of 2017 into law.

“The FDA Reauthorization Act of 2017 will play a key part in supporting the FDA and ensuring that American patients see the medicine and cures they have been promised. As Chairman of the Energy and Commerce Subcommittee on Health, I am proud to see this common sense, bipartisan legislation become law. I would like to thank my fellow Health Subcommittee members for their unwavering work on this legislation, overcoming distractions and setbacks to ensure that we could deliver on our promise to the American people. I am also grateful to the Senate and President Trump for their commitment to this cause.”